Thiamine
- Generic Name
- Thiamine
- Brand Names
- Alertonic, Concept Ob, Fortaplex, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Mvc-fluoride, Mvi Pediatric, Natafort, Neo-bex, Pregvit, Tandem Plus, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N4OS
- CAS Number
- 70-16-6
- Unique Ingredient Identifier
- 4ABT0J945J
- Background
Thiamine or thiamin, also known as vitamin B1, is a colorless compound with the chemical formula C12H17N4OS. It is soluble in water and insoluble in alcohol. Thiamine decomposes if heated. Thiamine was first discovered by Umetaro Suzuki in Japan when researching how rice bran cured patients of Beriberi. Thiamine plays a key role in intracellular glucose metabolism and it is thought that thiamine inhibits the effect of glucose and insulin on arterial smooth muscle cell proliferation. Thiamine plays an important role in helping the body convert carbohydrates and fat into energy. It is essential for normal growth and development and helps to maintain proper functioning of the heart and the nervous and digestive systems. Thiamine cannot be stored in the body; however, once absorbed, the vitamin is concentrated in muscle tissue.
- Indication
For the treatment of thiamine and niacin deficiency states, Korsakov's alcoholic psychosis, Wernicke-Korsakov syndrome, delirium, and peripheral neuritis.
- Associated Conditions
- Anemia, B12 Deficiency Anemia, Beriberi, Cardiovascular Heart Disease caused by Thiamine Deficiency, Folic Acid Deficiency Anemia, Infantile Beriberi, Infection, Iron Deficiency (ID), Neuritis caused by Pregnancy, Secondary anemia, Thiamine Deficiency, Vitamin Deficiency, Wernicke's encephalopathy, Liver disorders
- Associated Therapies
- Nutritional supplementation, Vitamin supplementation, Dietary supplementation
Neuroscientist's work leads to clinical trial for early Alzheimer's treatment
Gary Gibson hypothesizes that thiamine deficiency alters glucose metabolism in brain cells, leading to Alzheimer’s. His research culminated in the Benfoteam clinical trial evaluating benfotiamine, a thiamine precursor, for slowing Alzheimer’s progression. The trial aims to determine the highest safe dose and its efficacy in improving cognition and global function.
Decades of Work Leads to Clinical Trial for Early Alzheimer's Treatment
Dr. Gary Gibson hypothesizes that thiamine deficiency alters glucose metabolism in brain cells, leading to Alzheimer's. His research led to a nationwide clinical trial evaluating benfotiamine, an oral drug boosting thiamine levels, as a potential treatment.
Dr. Sara Szal Gottfried Explains the Health Impacts of All the Anger You're Feeling
Dr. Sara Szal Gottfried explains that stress responses like anxiety and anger can impact health if chronic, leading to issues like disrupted circadian rhythms, insomnia, and increased risk of heart attack. She suggests managing these emotions through awareness, controlled breathing, and meditation, while also recommending lifestyle changes such as reducing caffeine and alcohol intake.
How this clinical trial could help Alzheimer's patients
November is Alzheimer's Awareness Month; the Benfo Team Clinical Research is testing if vitamin B1 can enter the brains of early Alzheimer's patients, with trials in 50 cities including Stuart and Delray Beach. Participants with mild dementia or cognitive impairment aged 50-89 can join; for info, visit benfoteam.org or call 561-374-8461 (Delray Beach) or 772-223-7880 (Stuart).
FREEDOM2 Trial Shows Fedratinib's Efficacy and Safety in Myelofibrosis
Fedratinib (Inrebic) showed significant spleen volume reduction (SVR35) in myelofibrosis patients post-ruxolitinib, with 36% achieving SVR35 vs 6% in best available therapy (BAT) group. Gastrointestinal adverse effects were more common but manageable, and proactive thiamine supplementation reduced deficiency risk.
Gastroenterology Month in Review: September 2024
September 2024 saw FDA approval of guselkumab (Tremfya) for ulcerative colitis and a CRL for Vanda Pharmaceuticals’ tradipitant for gastroparesis. Research highlighted treatment dissatisfaction in IBS patients, key bacteria affecting IBD response to thiamine, and FMT delivery methods for IBS. Upper GI mucosal damage was linked to Parkinson disease risk, while MASLD and MetALD increased liver and gastrointestinal cancer risks. The 2024 GHAPP conference featured discussions on medication positioning in Crohn disease and managing gut-brain interaction disorders.
A PILL FOR ALZHEIMER'S DISEASE? CLINICAL TRIALS ON A NEW APPROACH TO TREATING MILD COGNITIVE IMPAIRMENT AND EARLY ALZHEIMER'S DISEASE
A national clinical trial, funded by the NIH, is testing a synthetic vitamin B1 (benfotiamine) developed by Burke Neurological Institute for treating mild cognitive impairment and early Alzheimer's disease. The trial, involving 50 sites across the U.S., aims to evaluate benfotiamine's effects on cognitive function and its potential to slow cognitive decline in participants aged 50-89. The study builds on research showing benfotiamine's ability to improve memory and reduce plaques, tangles, inflammation, and oxidative stress in animal models.
A PILL FOR ALZHEIMER'S DISEASE? CLINICAL TRIALS ON A NEW APPROACH TO ...
A national clinical trial, funded by NIH, tests benfotiamine, a synthetic vitamin B1, for treating mild cognitive impairment and early Alzheimer's disease. The trial, led by Burke Neurological Institute, UC San Diego, and Columbia University, aims to evaluate benfotiamine's cognitive effects and safety profile. Enrollment targets 406 participants aged 50-89 across 50 U.S. sites.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath